HTLV1 infection and long term association with liver function and lipid indices; 10 years' follow-up.
HTLV-I
Lipid profile
Liver
MASHAD study
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
28 Sep 2024
28 Sep 2024
Historique:
received:
04
03
2024
accepted:
23
09
2024
medline:
29
9
2024
pubmed:
29
9
2024
entrez:
28
9
2024
Statut:
epublish
Résumé
Human T-cell leukemia virus type 1 (HTLV-1) is a well-known retrovirus, particularly prevalent in northeastern Iran, where it is associated with a range of disorders, including liver dysfunction. Previous studies have demonstrated that HTLV-1 infection can alter lipid profiles, yet no research has examined lipid indices and liver function tests in these patients in the long term. This data is part of the Mashhad stroke and heart atherosclerotic disorder (MASHAD) study. A total of 1116 participants were randomly selected, including 837 healthy individuals and 279 HTLV-1-infected patients. Following a 10-year follow-up period, Serum levels of liver enzymes were measured. Lipid indices such as the Atherogenic Index of Plasma (AIP), Body Adiposity Index (BAC), Castelli risk index (CRI-I, CRI-II), Lipid Accumulation Product (LAP), Visceral Adiposity Index (VAI), Triglyceride-glucose index (TyG), and Triglyceride and HDL-C Ratio (THR) were calculated. Multivariable-adjusted regression analysis demonstrated a significant coefficient for the Visceral Adiposity Index (VAI) in HTLV-infected patients compared to healthy controls (B: -0.014, 95% CI: -0.02, 0.00, p = 0.046). However, no significant differences were observed in other lipid indices between HTLV-infected patients and healthy individuals. Regarding liver enzymes, significant variations were noted in HTLV-infected patients compared to healthy controls: Aspartate Aminotransferase (AST) (B: 2.978, 95% CI: 1.34, 4.61, p < 0.001), Alanine Aminotransferase (ALT) (B: 3.687, 95% CI: 1.59, 5.78, p = 0.001), Alkaline Phosphatase (ALP) (B: 18.232, 95% CI: 6.81, 29.65, p = 0.002), and Gamma-Glutamyl Transferase (GGT) (B: 3.714, 95% CI: 0.18, 7.24, p = 0.039). Individuals with HTLV-1 infection exhibit reduced VAI but elevated levels of liver enzymes such as AST, ALT, ALP, and GGT, indicating liver damage. These findings emphasize the virus's involvement in liver pathology. Also, HTLV-I is associated with reduced visceral fat tissue.
Sections du résumé
BACKGROUND
BACKGROUND
Human T-cell leukemia virus type 1 (HTLV-1) is a well-known retrovirus, particularly prevalent in northeastern Iran, where it is associated with a range of disorders, including liver dysfunction. Previous studies have demonstrated that HTLV-1 infection can alter lipid profiles, yet no research has examined lipid indices and liver function tests in these patients in the long term.
METHODS
METHODS
This data is part of the Mashhad stroke and heart atherosclerotic disorder (MASHAD) study. A total of 1116 participants were randomly selected, including 837 healthy individuals and 279 HTLV-1-infected patients. Following a 10-year follow-up period, Serum levels of liver enzymes were measured. Lipid indices such as the Atherogenic Index of Plasma (AIP), Body Adiposity Index (BAC), Castelli risk index (CRI-I, CRI-II), Lipid Accumulation Product (LAP), Visceral Adiposity Index (VAI), Triglyceride-glucose index (TyG), and Triglyceride and HDL-C Ratio (THR) were calculated.
RESULTS
RESULTS
Multivariable-adjusted regression analysis demonstrated a significant coefficient for the Visceral Adiposity Index (VAI) in HTLV-infected patients compared to healthy controls (B: -0.014, 95% CI: -0.02, 0.00, p = 0.046). However, no significant differences were observed in other lipid indices between HTLV-infected patients and healthy individuals. Regarding liver enzymes, significant variations were noted in HTLV-infected patients compared to healthy controls: Aspartate Aminotransferase (AST) (B: 2.978, 95% CI: 1.34, 4.61, p < 0.001), Alanine Aminotransferase (ALT) (B: 3.687, 95% CI: 1.59, 5.78, p = 0.001), Alkaline Phosphatase (ALP) (B: 18.232, 95% CI: 6.81, 29.65, p = 0.002), and Gamma-Glutamyl Transferase (GGT) (B: 3.714, 95% CI: 0.18, 7.24, p = 0.039).
CONCLUSION
CONCLUSIONS
Individuals with HTLV-1 infection exhibit reduced VAI but elevated levels of liver enzymes such as AST, ALT, ALP, and GGT, indicating liver damage. These findings emphasize the virus's involvement in liver pathology. Also, HTLV-I is associated with reduced visceral fat tissue.
Identifiants
pubmed: 39342192
doi: 10.1186/s12879-024-09980-z
pii: 10.1186/s12879-024-09980-z
doi:
Substances chimiques
Lipids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1067Subventions
Organisme : Mashhad University of Medical Sciences
ID : 4021736
Informations de copyright
© 2024. The Author(s).
Références
Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proceedings of the National Academy of Sciences. 1980;77(12):7415-9.
Hoshino H. Cellular factors involved in HTLV-1 entry and pathogenicit. Front Microbiol. 2012;3:222.
doi: 10.3389/fmicb.2012.00222
pubmed: 22737146
pmcid: 3380293
Rafatpanah H, Hedayati-Moghaddam MR, Fathimoghadam F, Bidkhori HR, Shamsian SK, Ahmadi S, et al. High prevalence of HTLV-I infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey. J Clin Virol. 2011;52(3):172–6.
doi: 10.1016/j.jcv.2011.07.004
pubmed: 21840754
Rafatpanah H, Torkamani M, Valizadeh N, Vakili R, Meshkani B, Khademi H, et al. Prevalence and phylogenetic analysis of HTLV-1 in a segregated population in Iran. J Med Virol. 2016;88(7):1247–53.
doi: 10.1002/jmv.24448
pubmed: 26680556
Pouliquen J-F, Hardy L, Lavergne A, Kafiludine E, Kazanji M. High seroprevalence of human T-cell lymphotropic virus type 1 in blood donors in Guyana and molecular and phylogenetic analysis of new strains in the Guyana shelf (Guyana, Suriname, and French Guiana). J Clin Microbiol. 2004;42(5):2020–6.
doi: 10.1128/JCM.42.5.2020-2026.2004
pubmed: 15131164
pmcid: 404635
van Tienen C, de Silva TI, Alcantara LCJ, Onyango CO, Jarju S, Gonçalves N, et al. Molecular epidemiology of endemic human T-lymphotropic virus type 1 in a rural community in Guinea-Bissau. PLoS Negl Trop Dis. 2012;6(6):e1690.
doi: 10.1371/journal.pntd.0001690
pubmed: 22720106
pmcid: 3373628
Magri MC, de Macedo Brigido LF, Rodrigues R, Morimoto HK, de Paula Ferreira JL, Caterino-de-Araujo A. Phylogenetic and similarity analysis of HTLV-1 isolates from HIV-coinfected patients from the south and southeast regions of Brazil. AIDS Res Hum Retroviruses. 2012;28(1):110–4.
doi: 10.1089/aid.2011.0117
pubmed: 21591992
pmcid: 3252815
Yutaka T, Masao M, Gallo R. 40 years of the human T-cell leukemia virus: past, present, and future. F1000Research. 2019;8.
Murphy EL, Glynn SA, Fride J, Sacher RA, Smith JW, Wright DJ, et al. Increased prevalence of infectious diseases and other adverse outcomes in human T lymphotropic virus types I-and II-infected blood donors. J Infect Dis. 1997;176(6):1468–75.
doi: 10.1086/514143
pubmed: 9395356
Boschi-Pinto C, Stuver S, Okayama A, Trichopoulos D, Orav EJ, Tsubouchi H, Mueller N. A follow-up study of morbidity and mortality associated with hepatitis C virus infection and its interaction with human T lymphotropic virus type I in Miyazaki, Japan. J Infect Dis. 2000;181(1):35–41.
doi: 10.1086/315177
pubmed: 10608748
Einsiedel LJ, Pham H, Woodman RJ, Pepperill C, Taylor KA. The prevalence and clinical associations of HTLV-1 infection in a remote indigenous community. Med J Aust. 2016;205(7):305–9.
doi: 10.5694/mja16.00285
pubmed: 27681971
Stuver SO, Tachibana N, Okayama A, Mueller NE. Evaluation of morbidity among human T lymphotropic virus type I carriers in Miyazaki, Japan. J Infect Dis. 1996;173(3):584–91.
doi: 10.1093/infdis/173.3.584
pubmed: 8627021
Murphy EL, Wang B, Sacher RA, Fridey J, Smith JW, Nass CC, et al. Respiratory and urinary tract infections, arthritis, and asthma associated with HTLV-I and HTLV-II infection. Emerg Infect Dis. 2004;10(1):109.
doi: 10.3201/eid1001.020714
pubmed: 15078605
pmcid: 3322766
Schierhout G, McGregor S, Gessain A, Einsiedel L, Martinello M, Kaldor J. Association between HTLV-1 infection and adverse health outcomes: a systematic review and meta-analysis of epidemiological studies. Lancet Infect Dis. 2020;20(1):133–43.
doi: 10.1016/S1473-3099(19)30402-5
pubmed: 31648940
Goon P, Bangham C. Interference with immune function by HTLV-1. Clin Experimental Immunol. 2004;137(2):234–6.
doi: 10.1111/j.1365-2249.2004.02524.x
Porto A, Santos S, Alcantara L, Guerreiro J, Passos J, Gonzalez T, et al. HTLV-1 modifies the clinical and immunological response to schistosomiasis. Clin Experimental Immunol. 2004;137(2):424–9.
doi: 10.1111/j.1365-2249.2004.02508.x
Hirata T, Nakamoto M, Nakamura M, Kinjo N, Hokama A, Kinjo F, Fujita J. Low prevalence of human T cell lymphotropic virus type 1 infection in patients with gastric cancer. J Gastroenterol Hepatol. 2007;22(12):2238–41.
doi: 10.1111/j.1440-1746.2006.04740.x
pubmed: 18031387
Arisawa K, Sobue T, Yoshimi I, Soda M, Shirahama S, Doi H, et al. Human T-lymphotropic virus type-I infection, survival and cancer risk in southwestern Japan: a prospective cohort study. Cancer Causes Control. 2003;14:889–96.
doi: 10.1023/B:CACO.0000003853.82298.96
pubmed: 14682446
Arisawa K, Soda M, Akahoshi M, Fujiwara S, Uemura H, Hiyoshi M, et al. Human T-cell lymphotropic virus type‐1 infection and risk of cancer: 15.4 year longitudinal study among atomic bomb survivors in Nagasaki, Japan. Cancer Sci. 2006;97(6):535–9.
doi: 10.1111/j.1349-7006.2006.00212.x
pubmed: 16734733
pmcid: 11158243
Silva MC, Silva CAC, Machado GU, Atta A, Freire M, Carvalho S. HCV/HTLV coinfection: does HTLV-1 interfere in the natural history of HCV‐related diseases? J Med Virol. 2016;88(11):1967–72.
doi: 10.1002/jmv.24538
pubmed: 27027482
Litvinova ЕS, Konoplya AI, Kholimenko IM, Kotsar A, RELATIONSHIP BETWEEN METABOLIC, AND IMMUNOLOGICAL INDICATORS AFTER CORRECTION BY ALLOGENIC HEPATOCYTES IN ACUTE TOXIC., ISCHEMIC AND ALCOHOL LIVER INJURY. Toxicological Review. 2021.
Mandal SK, Sil K, Chatterjee S, Ganguly J, Chatterjee K, Sarkar P, et al. A study on lipid profiles in chronic liver diseases. Natl J Med Res. 2013;3(01):70–2.
Kochan Z, Szupryczynska N, Malgorzewicz S, Karbowska J. Dietary lipids and dyslipidemia in chronic kidney disease. Nutrients. 2021;13(9).
Blesso CN, Fernandez ML. Dietary cholesterol, serum lipids, and Heart Disease: are Eggs Working for or against you? Nutrients. 2018;10(4).
Dai C-Y, Chuang W-L, Ho C-K, Hsieh M-Y, Huang J-F, Lee L-P, et al. Associations between Hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study. J Hepatol. 2008;49(1):9–16.
doi: 10.1016/j.jhep.2008.03.016
pubmed: 18486265
Hsu C-S, Liu C-J, Liu C-H, Chen C-L, Lai M-Y, Chen P-J, et al. Metabolic profiles in patients with chronic hepatitis C: a case–control study. Hep Intl. 2008;2:250–7.
doi: 10.1007/s12072-008-9064-3
Derakhshan R, Mirhosseini A, Ahmadi Ghezeldasht S, Jahantigh HR, Mohareri M, Boostani R, et al. Abnormal vitamin D and lipid profile in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients. Mol Biol Rep. 2020;47:631–7.
doi: 10.1007/s11033-019-05171-1
pubmed: 31713009
Ghayour-Mobarhan M, Moohebati M, Esmaily H, Ebrahimi M, Parizadeh SMR, Heidari-Bakavoli AR, et al. Mashhad stroke and heart atherosclerotic disorder (MASHAD) study: design, baseline characteristics and 10-year cardiovascular risk estimation. Int J Public Health. 2015;60:561–72.
doi: 10.1007/s00038-015-0679-6
pubmed: 25943424
Abolbashari S, Darroudi S, Tayefi M, Khashyarmaneh Z, Zamani P, Haghighi HM et al. Association between serum zinc and copper levels and antioxidant defense in subjects infected with human T-lymphotropic virus type 1. J Blood Med. 2018:29–35.
Dobiás̆ová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate inapob-lipoprotein-depleted plasma (FERHDL). Clin Biochem. 2001;34(7):583–8.
doi: 10.1016/S0009-9120(01)00263-6
pubmed: 11738396
Mahdavi-Roshan M, Mozafarihashjin M, Shoaibinobarian N, Ghorbani Z, Salari A, Savarrakhsh A, Hekmatdoost A. Evaluating the use of novel atherogenicity indices and insulin resistance surrogate markers in predicting the risk of coronary artery disease: a case–control investigation with comparison to traditional biomarkers. Lipids Health Dis. 2022;21(1):126.
doi: 10.1186/s12944-022-01732-9
pubmed: 36435770
pmcid: 9701407
Kahn HS. The lipid accumulation product performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord. 2005;5:1–10.
doi: 10.1186/1471-2261-5-26
Darroudi S, Soflaee SS, Hosseini ZS, Farmad MS, Mirshafiei H, Sheikh Andalibi MS, et al. The visceral adiposity index and lipid accumulation product as predictors of cardiovascular events in normal weight subjects. Clin Nutr ESPEN. 2022;52:190–7.
doi: 10.1016/j.clnesp.2022.10.015
pubmed: 36513453
TOLUNAY H. Triglyceride glucose index and the Triglyceride/HDL ratio as predictors of coronary artery disease. Düzce Üniversitesi Sağlık. Bilimleri Enstitüsü Dergisi. 2021;11(2):235–41.
Mirshafiei H, Darroudi S, Ghayour-Mobarhan M, Esmaeili H, AkbariRad M, Mouhebati M, Ferns GA. Altered triglyceride glucose index and fasted serum triglyceride high‐density lipoprotein cholesterol ratio predict incidence of cardiovascular disease in the Mashhad cohort study. BioFactors. 2022;48(3):643–50.
doi: 10.1002/biof.1816
pubmed: 35044705
Carvalho LDd, Gadelha SR, Marin LJ, Brito-Melo GEA, Martins CPS, Fonseca FGd, Barbosa-Stancioli EF. Are lipid disorders involved in the predominance of human T-lymphotropic virus-1 infections in women? Rev Soc Bras Med Trop. 2015;48:759–61.
doi: 10.1590/0037-8682-0068-2015
Bacelo A, Araújo A, Torres P, Brito P, de Almeida C, Fonseca C et al. ASSOCIATION BETWEEN NUTRITIONAL STATE AND PHASE ANGLE IN SYMPTOMATIC AND ASYMPTOMATIC HTLV-1 INFECTED PATIENTS2022.
Saghi E, Norouzy A, Nematy M, Jarahi L, Boostani R, Zemorshidi F, et al. Dietary intake and serum selenium levels influence the outcome of HTLV-1 infection. Biol Trace Elem Res. 2021;199(9):3242–52.
doi: 10.1007/s12011-020-02472-6
pubmed: 33169347
Martin F, Taylor GP, Jacobson S. Inflammatory manifestations of HTLV-1 and their therapeutic options. Expert Rev Clin Immunol. 2014;10(11):1531–46.
doi: 10.1586/1744666X.2014.966690
pubmed: 25340428
Garske KM, Kar A, Comenho C, Balliu B, Pan DZ, Bhagat YV, et al. Increased body mass index is linked to systemic inflammation through altered chromatin co-accessibility in human preadipocytes. Nat Commun. 2023;14(1):4214.
doi: 10.1038/s41467-023-39919-y
pubmed: 37452040
pmcid: 10349101
da Silva Costa LP, de França LG, Peniche GC, de Oliveira Castro AJ, da Silva Guterres A. Análise comparativa de dois métodos de avaliação nutricional aplicados em pacientes hospitalizados. Rev Bras Nutr Clin. 2012;27(1):24–8.
Ghaffari-Rafi A, Rho YS, Hall A, Villanueva N, Nogi M. HTLV-1 associated acute adult T-cell lymphoma/leukemia presenting as acute liver failure in Micronesian: a case report. Med (Baltim). 2021;100(28):e26236.
doi: 10.1097/MD.0000000000026236